PRC-063 Compared With Placebo for ADHD in Adults
About this title
Read the official source — NCT02139124Researchers compared PRC-063 25 mg, placebo, PRC-063 45 mg, PRC-063 70 mg and PRC-063 100 mg, tracking side effects to assess safety in adults with ADHD.
Understand this study
What did researchers investigate?
Researchers compared PRC-063 25 mg, placebo, PRC-063 45 mg, PRC-063 70 mg and PRC-063 100 mg, tracking side effects to assess safety in adults with ADHD.
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Los Angeles and 37 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 375
- Sponsor
- Rhodes Pharmaceuticals, L.P.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT02139124
- Official title
Show the full official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Los Angeles, United States · National City, United States · Newport Beach, United States
32 more locations
- Orange, United States
- Bradenton, United States
- Gainesville, United States
- Jacksonville, United States
- Maitland, United States
- Orlando, United States
- Tampa, United States
- Boise, United States
- Las Vegas, United States
- Princeton, United States
- New York, United States
- Raleigh, United States
- Cincinnati, United States
- Oklahoma City, United States
- Portland, United States
- Salem, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- Lubbock, United States
- Clinton, United States
- Salt Lake City, United States
- Woodstock, United States
- Herndon, United States
- Bellevue, United States
- Kirkland, United States
- Vancouver, Canada
- Niagara Falls, Canada
- Ottawa, Canada
- Whitby, Canada
- Sherbrooke, Canada
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared PRC-063 25 mg, placebo, PRC-063 45 mg, PRC-063 70 mg and PRC-063 100 mg, tracking side effects to assess safety in adults with ADHD.
Who is behind this study?
The study sponsor is Rhodes Pharmaceuticals, L.P.
Did this study involve medication?
Yes. The study involved medication, including Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg and PRC-063 100 mg.
Who was this study for?
Listed age limits: from 18 years.
